The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Spdr S&P Biotech Etf

NYSE: XBI
Last

(U.S.) $179.25

Today's change-1.26 -0.70%
Updated November 28 12:48 PM -5GMT. Delayed by at least 15 minutes.
 

Spdr S&P Biotech Etf

NYSE: XBI
Last

(U.S.) $179.25

Today's change-1.26 -0.70%
Updated November 28 12:48 PM -5GMT. Delayed by at least 15 minutes.

Reversal following new 52-week high

Spdr S&P Biotech Etf closed lower Friday, dropping (U.S.)$1.26 or 0.70% to (U.S.)$179.25 after setting a new 52-week high. Over the last five days, shares have gained 2.99% and are currently 2.67% off of the 52-week high. Shares have outperformed the S&P 500 by 24.30% during the last year.

Key company metrics

  • Open(U.S.) $180.93
  • Previous close(U.S.) $180.51
  • High(U.S.) $184.16
  • Low(U.S.) $179.25
  • Bid / Ask(U.S.) $179.27 / (U.S.) $179.41
  • YTD % change+37.67%
  • Volume236,944
  • Average volume (10-day)256,783
  • Average volume (1-month)352,725
  • Average volume (3-month)418,720
  • 52-week range(U.S.) $115.31 to (U.S.) $184.16
  • Beta1.13
  • Trailing P/E4.50×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $1.55
  • Dividend yield0.86%
  • Trailing EPS(U.S.) $39.84
Updated November 28 12:48 PM -5GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+6,254.35%

The data is not available to provide analysis on this topic.
Company Books

S&P TSX0.90%Sector:FinancialsIndustry:Investment Trusts
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2014Q4/2013Q2/2013Q4/2012
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201312/31/2013Jun 30, 201306/30/2013Dec 31, 201212/31/2012Jun 30, 201206/30/2012
Revenue3231
Total other revenue--------
Total revenue3231
Gross profit--------
Total cost of revenue--------
Total operating expense2111
Selling / general / administrative2111
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total0000
Operating income1110
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax200125-11147
Income after tax200125-11147
Income tax, total0000
Net income200125-11147
Total adjustments to net income--------
Net income before extra. items200125-11147
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items200125-11147
Inc. avail. to common incl. extra. items200125-11147
Diluted net income200125-11147
Dilution adjustment----0--
Diluted weighted average shares8978
Diluted EPS excluding extraordinary itemsvalue per share26.0113.83-1.5018.31
Dividends per sharevalue per share0.130.090.200.00
Diluted normalized EPSvalue per share26.0113.83-1.5018.31